Other work has identified FMRP as a potential target for cancer immunotherapy, as it regulates immune cell metabolism, suggesting that inhibition of FMRP could overcome resistance to anti–PD-1, anti–PD-L1, and anti–CTLA-4 therapies. Here, CTLA4 is linked to cancer.